Development, Safety, Issues, and Challenges of the SARS-CoV-2 Vaccine-Reference-Cited by-同舟云学术

Development, Safety, Issues, and Challenges of the SARS-CoV-2 Vaccine

Published:2023-03-01 Issue:3 Volume:11 Page:569
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Matsuzaka Yasunari¹²,Yashiro Ryu²³

Affiliation:

1. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, University of Tokyo, Minato-ku 108-8639, Tokyo, Japan

2. Administrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira 187-8551, Tokyo, Japan

3. Department of Infectious Diseases, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi 181-8611, Tokyo, Japan

Abstract

It has been reported that some mutant strains of the new coronavirus escape from neutralizing antibodies acquired by recoverees and vaccine recipients, in which the Omicron strain (B [...]

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/3/569/pdf

Reference14 articles.

1. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity;Lam;medRxiv,2021

2. Influenza Vaccines: Successes and Continuing Challenges;Becker;J. Infect. Dis.,2021

3. Overview of recent advances in Vero cells genomic characterization and engineering for high-throughput vaccine manufacturing;Xia;Clin. Transl. Med.,2022

4. The clinical progress of mRNA vaccines and immunotherapies;Barbier;Nat. Biotechnol.,2022

5. Yen, A.M., Chen, S.L., Hsu, C.Y., and Chen, T.H. (2022). The Preventive Role of mRNA Vaccines in Reducing Death among Moderate Omicron-Infected Patients: A Follow-Up Study. Viruses, 14.